Clinical Trials Directory

Trials / Unknown

UnknownNCT00279227

Role of Epicardial Adipose Tissue in Coronary Artery Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (planned)
Sponsor
Hamilton Health Sciences Corporation · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

We sight to evaluate whether patients with coronary artery disease (CAD) have more epicardial fat than patients without CAD, which would suggest that epicardial fat may be more than an "innocent bystander" and be actively involved in the disease process. Its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. We also sight to evaluate whether epicardial fat from patients with CAD releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. Thus for e.g., the use of thiazolidinediones (glitazones), statins, ARBs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.

Conditions

Timeline

Start date
2006-01-01
Completion
2006-12-01
First posted
2006-01-19
Last updated
2006-08-15

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00279227. Inclusion in this directory is not an endorsement.